Literature DB >> 10504417

Expression, partial purification and functional properties of themuscle-specific calpain isoform p94.

D Branca1, A Gugliucci, D Bano, M Brini, E Carafoli.   

Abstract

The muscle-specific calpain isoform p94 has high propensity to autocatalytic degradation, thus no significant amounts of the intact active protein have been available so far. As a result, aspects like its regulation (via Ca2+ and other factors) and its intracellular localization are unknown or obscure. In this work, large amounts of human p94 have been produced in insect cells using a recombinant baculovirus expression system. Although most of the protease was recovered in an insoluble and catalytically inactive form, the soluble fraction contained amounts of intact active p94 adequate for its characterization. His-tagged recombinant p94, obtained by the same expression system, was partially purified as an active product. Both the unmodified and the partially purified His-tagged p94 bound calcium with high affinity, and their autolytic activity required Ca2+. The sensitivity of the catalytic activity of the recombinant protease to Ca2+ was very high. In fact, p94 in soluble cell extracts autolysed to a significant extent even in the presence of submicromolar Ca2+ levels. Thus, in analogy to what demonstrated for the ubiquitous m- and micro-calpain isoforms, intracellular Ca2+ might be one of the factors controlling the activity of this muscle-specific calpain isoform.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10504417     DOI: 10.1046/j.1432-1327.1999.00817.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  18 in total

1.  Homodimerization of calpain 3 penta-EF-hand domain.

Authors:  Ravikiran Ravulapalli; Beatriz Garcia Diaz; Robert L Campbell; Peter L Davies
Journal:  Biochem J       Date:  2005-06-01       Impact factor: 3.857

2.  Disruption of excitation-contraction coupling and titin by endogenous Ca2+-activated proteases in toad muscle fibres.

Authors:  Esther Verburg; Robyn M Murphy; D George Stephenson; Graham D Lamb
Journal:  J Physiol       Date:  2005-03-03       Impact factor: 5.182

3.  Ca2+ activation of diffusible and bound pools of mu-calpain in rat skeletal muscle.

Authors:  Robyn M Murphy; Esther Verburg; Graham D Lamb
Journal:  J Physiol       Date:  2006-07-20       Impact factor: 5.182

4.  The blockade of dihydropyridine channels prevents an increase in μ-calpain level under m. soleus unloading.

Authors:  S P Belova; Yu N Lomonosova; B S Shenkman; T L Nemirovskaya
Journal:  Dokl Biochem Biophys       Date:  2015-03-13       Impact factor: 0.788

Review 5.  Mechanisms of stretch-induced muscle damage in normal and dystrophic muscle: role of ionic changes.

Authors:  D G Allen; N P Whitehead; E W Yeung
Journal:  J Physiol       Date:  2005-07-07       Impact factor: 5.182

6.  Regulation of the M-cadherin-beta-catenin complex by calpain 3 during terminal stages of myogenic differentiation.

Authors:  Irina Kramerova; Elena Kudryashova; Benjamin Wu; Melissa J Spencer
Journal:  Mol Cell Biol       Date:  2006-09-18       Impact factor: 4.272

7.  The role of proteases in excitation-contraction coupling failure in muscular dystrophy.

Authors:  Davi A G Mázala; Robert W Grange; Eva R Chin
Journal:  Am J Physiol Cell Physiol       Date:  2014-10-08       Impact factor: 4.249

8.  Characterization of endogenous and recombinant human calpain-10.

Authors:  Biao Dong; Rihe Liu
Journal:  Biochimie       Date:  2008-04-10       Impact factor: 4.079

9.  Endogenous calpain-3 activation is primarily governed by small increases in resting cytoplasmic [Ca2+] and is not dependent on stretch.

Authors:  Robyn M Murphy; Graham D Lamb
Journal:  J Biol Chem       Date:  2009-01-14       Impact factor: 5.157

10.  Epidermal growth factor activates m-calpain (calpain II), at least in part, by extracellular signal-regulated kinase-mediated phosphorylation.

Authors:  A Glading; R J Bodnar; I J Reynolds; H Shiraha; L Satish; D A Potter; H C Blair; A Wells
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.